Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-09-08 00:00:00 ET · period of report 2025-09-05 · accession 0001257809-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-08 | 2025-09-05 | BBIO | MCCORMICK FRANK | Dir | S - Sale+OE | $53.16 | -74.0K | 83.3K | -47% | -$3.93M |
| D | 2025-09-08 | 2025-09-05 | BBIO | MCCORMICK FRANK | Dir | M - OptEx | $11.92 | +74.0K | 157.3K | +89% | +$882.1K |
| D | 2025-09-08 | 2025-09-05 | BBIO | MCCORMICK FRANK | Dir | M - OptEx | $0.00 | -74.0K | 84.8K | -47% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-05 | S | D | 74,000 | $53.16 | 83,275 | D | — | — | (F1) Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-09-05 | M | A | 74,000 | $11.92 | 157,275 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-09-05 | M | D | 74,000 | $0.00 | 84,814 | D | $11.92 · — to 2033-02-20 | 74,000 Common Stock | (F2) The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. |